GR 2102
Alternative Names: GR-2102Latest Information Update: 06 Sep 2024
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 23 Mar 2024 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in China (Injection) (NCT06313697)
- 15 Mar 2024 Genrix (Shanghai) Biopharmaceutical plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (Injection) (NCT06313697)
- 15 Mar 2024 Preclinical trials in Respiratory syncytial virus infections in China (Injection), prior to March 2024